| Literature DB >> 30808307 |
Jiangtian Tian1,2, Xuedong Wang2, Jinwei Tian3, Bo Yu4,5.
Abstract
BACKGROUND: Although numerous reports suggest sex-related differences in atherosclerosis, limited data describing gender-associated differences in plaque morphology and composition are currently available. The aim of the present study was to compare coronary nonculprit plaque characteristics in women and men with coronary artery disease (CAD) by optical coherence tomography (OCT).Entities:
Keywords: Coronary artery disease; Gender; Nonculprit plaque; Optical coherence tomography; Plaque characteristic
Mesh:
Substances:
Year: 2019 PMID: 30808307 PMCID: PMC6390304 DOI: 10.1186/s12872-019-1023-5
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Fig. 1The patient count breakdown outline
Fig. 2Representative optical coherence tomography images. a TCFA, defined as a lipid-rich plaque with a fibrous cap thickness < 65 μm (arrows). b Microvessels are represented by black holes within the plaque (arrow). c Cholesterol crystals are reflected by thin, linear regions of high intensity within the plaque (arrows). d Macrophage accumulation on OCT images, defined as increased signal intensity within the fibrous cap, accompanied by heterogeneous backward shadows (arrows). e Calcification is reflected by an area with low backscatter signal and a sharp border (arrows). f Plaque disruption showing discontinuity of the fibrous cap. g White (platelet-rich) thrombus is represented by low and homogeneous backscattering with low signal attenuation (arrow). h Red (red blood cell-rich) thrombus is represented by high backscattering with high attenuation (arrows)
Baseline clinical characteristics
| Variable | Men, | Women, | |
|---|---|---|---|
| Age, y | 60.8 ± 9.8 | 70.8 ± 7.3 | < 0.001 |
| Risk factors | |||
| Hypertension, n (%) | 47 (61.4) | 13 (50.0) | 0.324 |
| Dyslipidemia, n (%) | 39 (50.6) | 15 (57.7) | 0.534 |
| Diabetes mellitus, n (%) | 31 (40.3) | 10 (38.5) | 0.871 |
| Current smoker, n (%) | 23 (29.9) | 1 (3.8) | 0.007 |
| Medications before admission | |||
| Aspirin, n (%) | 63 (81.8) | 22 (84.6) | 0.745 |
| Statins, n (%) | 57 (74.0) | 21 (80.8) | 0.488 |
| β-Blockers, n (%) | 29 (37.7) | 10 (38.5) | 0.942 |
| ACE inhibitors, n (%) | 19 (24.7) | 7 (26.9) | 0.820 |
| Biochemistry data | |||
| TC, mg/dL | 151.6 ± 37.5 | 166.6 ± 37.5 | 0.082 |
| LDL-C, mg/dL | 79.4 ± 27.6 | 92.2 ± 27.0 | 0.043 |
| HDL-C, mg/dL | 40.2 ± 7.6 | 43.1 ± 12.6 | 0.164 |
| TG, mg/dL | 178.4 ± 167.7 | 149.9 ± 65.2 | 0.402 |
| HbA1c, % | 6.6 ± 1.3 | 6.9 ± 1.5 | 0.415 |
| hs-CRP, mg/L | 3.0 ± 2.8 | 1.6 ± 1.3 | 0.082 |
| Creatinine, mg/L | 0.9 ± 0.2 | 0.8 ± 0.2 | 0.018 |
| Fasting glucose, mg/L | 116.1 ± 41.8 | 139.1 ± 68.0 | 0.113 |
Abbreviations: HbA glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, hs-CRP high-sensitivity C-reactive protein, IQR interquartile range, LDL-C low-density lipoprotein cholesterol, TC total cholesterol, TG triglycerides. Data are n (%) or mean ± SD
Angiographic findings
| Variable | Men, | Women, | |
|---|---|---|---|
| Plaque location, n (%) | 0.739 | ||
| LAD, n (%) | 45 (33.3) | 15 (28.8) | |
| LCX, n (%) | 37 (27.4) | 17 (32.7) | |
| RCA, n (%) | 53 (39.3) | 20 (38.5) | |
| Multivessel disease, n (%) | 38 (49.4) | 13 (50.0) | 0.954 |
| QCA findings | |||
| lesion length, mm | 9.4 ± 4.5 | 7.3 ± 4.3 | 0.024 |
| RVD, mm | 3.0 ± 0.5 | 3.0 ± 0.6 | 0.640 |
| MLD, mm | 1.9 ± 0.4 | 1.9 ± 0.4 | 0.645 |
| Diameter stenosis, % | 37.3 ± 7.6 | 36.9 ± 7.7 | 0.750 |
Abbreviations: LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery; QCA, MLD minimum lumen diameter, RVD reference vessel diameter, Data are n (%) or mean ± SD
Optical coherence tomography (OCT) findings
| Variables | Men, | Women, | |
|---|---|---|---|
| MLA, mm2 | 3.1 ± 1.3 | 3.1 ± 1.3 | 0.746 |
| Mean RVA, mm2 | 7.1 ± 2.5 | 7.3 ± 2.7 | 0.684 |
| Stenosis area, % | 42.6 ± 11.0 | 42.9 ± 10.8 | 0.880 |
| Lipid-rich plaque | |||
| Lipid-rich, n (%) | 87 (64.4) | 35 (67.3) | 0.713 |
| Maximum lipid arc | 224.1 ± 63.6 | 210.0 ± 58.5 | 0.259 |
| Lipid length, mm | 9.4 ± 4.5 | 7.3 ± 4.3 | 0.024 |
| Lipid index | 1615.1 ± 893.8 | 1237.8 ± 859.8 | 0.035 |
| FCT, μm | 89.2 ± 34.9 | 93.4 ± 48.2 | 0.597 |
| TCFA, n (%) | 29 (37.7) | 12 (46.2) | 0.444 |
| Disruption, n (%) | 4 (3.0) | 5 (9.6) | 0.057 |
| Calcification, n (%) | 42 (31.1) | 15 (28.8) | 0.763 |
| Macrophage, n (%) | 42 (31.1) | 17 (32.7) | 0.835 |
| Microvessels (MC), n (%) | 50 (37.0) | 27 (51.9) | 0.064 |
| Cholesterol crystal, n (%) | 12 (8.9) | 5 (9.6) | 0.670 |
| Thrombus, n (%) | 2 (1.5) | 3 (5.7) | 0.103 |
Abbreviations: FCT fibrous cap thickness, IQR interquartile range, MLA minimum lumen area, RVA reference vessel area, SD standard deviation, TCFA thin-cap fibroatheroma. Data are n (%) or mean ± SD
Univariate and Multivariate Linear Regression Models for Lipid Index
| Univariate Model | Multivariate Model | |||
|---|---|---|---|---|
| β Coefficient | β Coefficient | |||
| Age | −21.012 | 0.004 | −2.879 | 0.772 |
| Sex | 375.867 | 0.037 | 266.559 | 0.259 |
| Hypertension | 83.188 | 0.626 | 158.827 | 0.397 |
| Dyslipidemia | 221.820 | 0.458 | 552.927 | 0.097 |
| Current smoker | 469.748 | 0.014 | 163.004 | 0.474 |
| Diabetes mellitus | 304.668 | 0.070 | 230.157 | 0.171 |
| Statins | − 644.889 | 0.000 | − 783.199 | 0.023 |
| β-Blockers | −226.489 | 0.171 | 9.594 | 0.961 |
| Aspirin | −510.237 | 0.014 | 307.245 | 0.447 |
| TC | −0.383 | 0.855 | −0.688 | 0.889 |
| LDL-C | 3.453 | 0.200 | 1.754 | 0.769 |
| HDL-C | −0.103 | 0.991 | 4.501 | 0.659 |
| TG | −0.743 | 0.142 | −0.617 | 0.486 |
Abbreviations: HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TC total cholesterol, TG triglycerides. P values are from the inference using the generalized estimating equation–based sandwich SE estimates